RAMUCIRUMAB (LY3009806)

VEGF RECEPTOR-2 ANTAGONIST

The safety and efficacy of the agents for uses under investigation have not been established. Pipeline molecules may not receive regulatory approval and become commercially available for the uses being investigated. The information provided about new molecules being studied is for scientific information exchange purposes only with no commercial intent. For more information on our pipeline, please visit lillyloxooncologypipeline.com.

This document was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.

RAMUCIRUMAB VEGF RECEPTOR-2 ANTAGONIST (LY3009806) | MECHANISM OF ACTION[1,2]



Adams RH, et al[1]; Hicklin DJ, et al[2]

Abbreviations: PlGF=Placental Growth Factor; VEGF-A=Vascular Endothelial Growth Factor A; VEGF-B=Vascular Endothelial Growth Factor B; VEGF-C=Vascular Endothelial Growth Factor C; VEGF-D=Vascular Endothelial Growth Factor D; VEGFR1=Vascular Endothelial Growth Factor Receptor 1; VEGFR2=Vascular Endothelial Growth Factor Receptor 2; VEGFR3=Vascular Endothelial Growth Factor Receptor 3.

References: 1. Adams RH, Alitalo K. *Nat Rev Mol Cell Biol.* 2007;8(6):464-478. **2.** Hicklin DJ, Ellis LM. *J Clin Oncol.* 2005;23(5):1011-1027.

The safety and efficacy of the agents for uses under investigation have not been established. Pipeline molecules may not receive regulatory approval and become commercially available for the uses being investigated. The information provided about new molecules being studied is for scientific information exchange purposes only with no commercial intent. For more information on our pipeline, please visit lillyloxooncologypipeline.com.

This document was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.

RAMUCIRUMAB VEGF RECEPTOR-2 ANTAGONIST (LY3009806)

TARGET

Angiogenesis is a tightly regulated, multiple-step process, which results in the formation of new blood vessels from preexisting vasculature and is an important component in the development and progression of malignant disease. Signaling by vascular endothelial growth factor (VEGF) receptor-2 in endothelial cells plays a role in inducing normal and pathologic angiogenesis and is activated by binding of ligands VEGF-A, VEGF-C, and VEGF-D.[1-3]

MOLECULE

Ramucirumab is a human IgG1 monoclonal antibody receptor antagonist that has been shown *in vitro* to bind to and block the activation of VEGF receptor-2 by preventing the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D.[4,5]

CLINICAL DEVELOPMENT

Ramucirumab is being investigated in clinical trials in patients with non-small cell lung cancer or pediatric sarcoma.

References: 1. Adams RH, Alitalo K. *Nat Rev Mol Cell Biol.* 2007;8(6):464-478. **2.** Hicklin DJ, Ellis LM. *J Clin Oncol.* 2005;23(5):1011-1027. **3.** Olsson AK, et al. *Nat Rev Mol Cell Biol.* 2006;7(5):359-371. **4.** Lu D, et al. *J Biol Chem.* 2003;278(44):43496-43507. **5.** Zhu Z, et al. *Leukemia.* 2003;17(3):604-611.

The safety and efficacy of the agents for uses under investigation have not been established. Pipeline molecules may not receive regulatory approval and become commercially available for the uses being investigated. The information provided about new molecules being studied is for scientific information exchange purposes only with no commercial intent. For more information on our pipeline, please visit lillyloxooncologypipeline.com.

This document was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.

ACTIVE TRIALS CURRENTLY NOT ENROLLING

[NCT02411448] Lung Cancer
RELAY: A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With *EGFR* Mutation-Positive Metastatic NSCLC

[NCT04145349] Pediatric Cancer
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

[NCT02791334] Solid Tumor
PACT: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

[NCT02711553] Biliary Tract Cancer
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

The safety and efficacy of the agents for uses under investigation have not been established. Pipeline molecules may not receive regulatory approval and become commercially available for the uses being investigated. The information provided about new molecules being studied is for scientific information exchange purposes only with no commercial intent. For more information on our pipeline, please visit lillyloxooncologypipeline.com.

This document was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.

Pipeline information is current through July 25, 2024.